Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
暂无分享，去创建一个
H. Lenz | V. Heinemann | W. Zhang | S. Okazaki | D. Yang | F. Loupakis | A. Falcone | S. Matsusaka | S. Stintzing | Y. Miyamoto | M. D. Berger | S. Cao | S. Soni | Y. Ning | M. Schirripa | Y. Sunakawa | M. Suenaga